Sitafloxacin (INN; also called DU-6859a) is a fluoroquinolone antibiotic[1] that shows promise in the treatment of Buruli ulcer. The molecule was identified by Daiichi Sankyo Co., which brought ofloxacin and levofloxacin to the market. Sitafloxacin is currently marketed in Japan by Daiichi Sankyo under the tradename Gracevit.[citation needed]
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H18ClF2N3O3 |
Molar mass | 409.82 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
See also
editReferences
edit- ^ Anderson DL (July 2008). "Sitafloxacin hydrate for bacterial infections". Drugs of Today. 44 (7): 489–501. doi:10.1358/dot.2008.44.7.1219561. PMID 18806900.
Further reading
editExternal links
edit- (in Japanese) Gracevit グレースビット (PDF) Daiichi Sankyo Co. January 2008.